The Latest Breaking News from Laura Chico

Travere Therapeutics stock popped Wednesday after a group of experts suggested an alternative means of measuring the success of FSGS drugs.

Biogen stock has mostly trended sideways this year, but that could soon change with up to $10 billion in dry powder, an analyst said Tuesday.

Biogen stock rose Wednesday after the FDA posted documents that suggest the agency will approve Alzheimer's treatment Leqembi.

Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.

Apellis Pharmaceuticals’ (APLS) stock has jumped more than 25% year-to-date based on FDA approval for treating geographic atrophy. Despite the breakthrough, the company’s ability to scale up production remains a concern. Moreover, its closest competitor is also close to getting approval. Given its poor financials, stretched valuation, and weak profitability,…

A kidney disease treatment from Vera lagged rivals from Chinook and Otsuka, analysts said Wednesday as the biotech stock plummeted.

The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders.

Apellis reported an unexpected delay for its eye-disease treatment, leading APLS stock to crash and taking shares of Iveric with it.

The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.